Loading organizations...
§ Public · San Diego, CA, USA
Biotechnology company developing therapeutics for liver diseases, focused on caspase inhibitors like Emricasan.
Conatus Pharmaceuticals was a San Diego, California-based biotechnology company focused on developing innovative therapeutics for chronic liver diseases caused by viral infections, obesity, and autoimmune issues. The pre-commercial firm advanced its lead candidate, a caspase inhibitor named Emricasan, through multiple clinical trials in partnership with Novartis to treat conditions like nonalcoholic steatohepatitis. Initially backed by venture capital firms including Advent Life Sciences, the company transitioned to the public markets through a July 2013 initial public offering on the NASDAQ exchange. Following the failure of its third mid-stage clinical trial in 2019, the organization laid off 40 percent of its workforce and subsequently ceased independent operations via a 2020 reverse merger with Histogen. Conatus Pharmaceuticals was founded in 2005 by Steven J. Mento alongside the former executive management team members of Pfizer-acquired Idun Pharmaceuticals.
Conatus Pharmaceuticals has raised $50.0M across 3 funding rounds.
Conatus Pharmaceuticals has raised $50.0M in total across 3 funding rounds.
Conatus Pharmaceuticals has raised $50.0M in total across 3 funding rounds.
Conatus Pharmaceuticals's investors include MPM Capital, Louis Lacasse, Aberdare Ventures, Advent Life Sciences, Shahzad Malik, William Gerber, Roche, Advent Venture Partners, Bay City Capital.
Conatus Pharmaceuticals has raised $50.0M across 3 funding rounds. Most recently, it raised $8.0M Series B in April 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2011 | $8M Series B | MPM Capital | — | Announced |
| Feb 1, 2011 | $20M Series B | Louis Lacasse | Aberdare Ventures, Advent Life Sciences, Shahzad Malik, William Gerber, Roche | Announced |
| May 1, 2007 | $22M Series A | — | Aberdare Ventures, Advent Life Sciences, Advent Venture Partners, BAY City Capital | Announced |
Conatus Pharmaceuticals is a biotechnology company, not a technology company in the software or hardware sense, focused on developing innovative medicines for liver diseases such as chronic liver disease, cirrhosis, and related conditions like Hepatitis C Virus (HCV).[1][2][3][4] Its lead programs included CTS-1027 (in Phase 2 trials for HCV) and Emricasan (a caspase inhibitor advanced to clinical stages for liver cirrhosis and acute exacerbations), targeting mechanisms like caspase inhibition to address unmet needs in a market affecting 5.5 million Americans, where liver disease ranks as the 12th leading cause of death.[1][2][5] The company served patients with liver disorders, solving problems of disease progression and acute flares through novel therapeutics, with growth marked by an IPO on NASDAQ (CNAT) in 2013 and multiple financings, though many pipeline candidates like Emricasan, IDN-1529, and RS-130830 were later discontinued.[2][5]
Conatus Pharmaceuticals emerged around 2006, licensing its initial lead candidate CTS-1027 from Hoffmann-La Roche to focus on liver disease and cancer therapeutics.[1][2] Key early leaders included executives with deep biotech pedigrees: a CEO who previously led Idun Pharmaceuticals from discovery to clinical stages before its 2005 sale to Pfizer; a VP of Development managing partnerships like those with Abbott; and a co-founder/SVP of Corporate Development who negotiated acquisitions including Pfizer's Idun subsidiary.[1] Pivotal moments included a $20 million Series B financing with investors like Gilde Healthcare and Bay City Capital, acquisition of Pfizer's Idun assets, Phase 2 trial initiations for CTS-1027, and the 2013 NASDAQ IPO, building early traction in inflammation and liver disease.[2][3]
Conatus rode the early 2010s biotech wave in targeted liver therapies, capitalizing on rising awareness of chronic liver disease amid HCV epidemics and cirrhosis burdens, with market forces like aging populations and unmet needs for non-invasive treatments favoring caspase-focused innovations.[2][4] Its timing aligned with advances in understanding apoptosis in liver fibrosis, influencing the ecosystem by validating acquisitions from Big Pharma (e.g., Pfizer, Roche) and paving paths for IPOs in niche inflammation spaces, though discontinued pipelines highlight biotech risks in late-stage trials.[1][5] As a San Diego-based player, it contributed to the region's biotech cluster, bridging discovery-to-development transitions seen in predecessors like Idun.[1][2]
Conatus achieved key milestones like IPO and clinical progress but faced setbacks with discontinued assets like Emricasan, reflecting high biotech attrition; post-2013, it appears inactive as a going concern, with no recent developments noted.[2][5][6] Emerging trends in gene therapies and precision medicine for liver diseases (e.g., NASH/fibrosis) could inspire similar caspase approaches, but Conatus's legacy lies in proving viable paths for liver-focused biotechs amid evolving markets. Its influence may evolve through alumni networks and acquired IP, underscoring the sector's pivot from small molecules to next-gen modalities.[1][5]